Answers are grounded in this paper and cite their sources.
Comprehensive review highlights effective dosing strategies for valganciclovir, indicating key optimization challenges.
Accumulating evidence indicates that GCV exposure is associated with both efficacy and safety and exposure-guided dosing (target area under the time - concentration curve (AUC) of 40-60 μg·h/mL) may provide a reliable approach for maximizing VGCV therapy. However, several methodological and practical challenges, including standardization of LSS and improvement of microsampling technologies, are required for practical VGCV dose optimization in all patient populations.
No takes yet. Share an insight, caveat, or question.
Itohara et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: